Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of QIVc in Children 6 to 47 Months
NCT03932682Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- May 2019
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of influenza vaccine (cell-based) in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoints: First Occurrence of Reverse Transcription-polymerase Chain Reaction (RT-PCR) Confirmed Influenza and First Occurrence of Culture Confirmed Influenza, Due to Influenza Type A and/or B Virus Antigenically Matched. Started May 2019; status: completed.
02
Drugs
influenza vaccine (cell-based)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03932682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932682.